GlassScriptPhysician profile
Toby A Murray
NPI 1508092834
$4,083.27
in general payments reported to CMS, 2019-2025
37 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $684 · 2024: $1,433 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,648 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,648.40 |
| Education | $434.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $442.68 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $399.18 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $323.32 | 2023-2025 | Erleada, Balversa, Talvey |
| Incyte Corporation | $265.15 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $259.79 | 2024-2025 | Padcev, Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $238.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $217.83 | 2023-2025 | Libtayo |
| Glaxosmithkline, LLC. | $209.20 | 2023-2025 | Ojjaara, Jemperli |
| Genentech USA, INC. | $196.07 | 2023-2025 | Polivy, Tecentriq, Itovebi |
| Astrazeneca Pharmaceuticals LP | $165.30 | 2023-2025 | Calquence, Tagrisso, Imfinzi |
| Celgene Corporation | $162.93 | 2023-2025 | Reblozyl, Opdualag |
| Eisai INC. | $152.08 | 2023-2025 | |
| Stemline Therapeutics INC. | $121.58 | 2023-2025 | Orserdu |
| Genzyme Corporation | $110.13 | 2023-2024 | |
| Beigene USA, INC. | $86.61 | 2024-2025 | Brukinsa |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toby Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.